Cann Pharmaceutical Australia Limited (CPA), a clinical-stage biopharmaceutical company focused on phyto-cannabinoid treatments for epilepsy disorders, recently announced successful approval of the first Phase 2a clinical trial of its lead candidate, EP1, for the treatment of medication resistant, refractory epilepsy.
This clinical trial is a multi-centre, randomised, double-blind, placebo-controlled study evaluating safety, tolerability, efficacy and PK of EP1 compared to placebo. EP1 contains Cannabidiol (CBD) and Tetrahydrocannabinol (THC) in a ratio of approximately 20:1. The study will aim to determine if EP1 is an effective treatment for refractory epilepsy in children, adolescents and young adults by comparing different doses of EP1 against a placebo by measuring seizure frequency and character. Safety will also be measured over a long term open-label extension of the study for a year after the double blind phase. For details, please see
Epilepsy is one of the most common neurological diseases globally, yet currently available pharmacological therapies are ineffective in around 30% of patients, leaving many millions of patients searching for an effective treatment. Although the exact mechanism is unclear, the active components of medicinal cannabis; Δ9- tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown anticonvulsant activity in preclinical models of epilepsy and may provide another treatment option for patients with refractory epilepsy.
CPA also has a deep pipeline of additional cannabinoid product candidates targeting adult epilepsy, autism, a number of cancers, pain and neurological conditions caused by damage to the central nervous system and terminal illnesses. CPA's drug discovery and development process pipeline extends to other cancers where patients are refractory to current therapeutic treatment.